PPARG and benign prostatic hyperplasia: We also demonstrate that SV ameliorates the progression of BPH both in vivo and in vitro through apoptosis, cell cycle arrest at the G0/G1 phase, attenuation of tissue fibrosis, and the EMT process via upregulating PPARγ and inhibiting the WNT/β-catenin pathway.